Protein Kinase Inhibitors
From Discovery to Therapeutics
- 1st Edition - May 19, 2022
- Imprint: Academic Press
- Editors: Md. Imtaiyaz Hassan, Saba Noor
- Language: English
- Paperback ISBN:9 7 8 - 0 - 3 2 3 - 9 1 2 8 7 - 7
- eBook ISBN:9 7 8 - 0 - 3 2 3 - 9 1 3 4 9 - 2
Protein Kinase Inhibitors: From Discovery to Therapeutics offers a foundational, pragmatic overview of protein kinases inhibitors and their potential role in disease modulatio… Read more
Purchase options
Protein Kinase Inhibitors: From Discovery to Therapeutics offers a foundational, pragmatic overview of protein kinases inhibitors and their potential role in disease modulation and treatment. Here, international experts in the field offer an integrated discussion of kinase inhibitor biology, biomarker discovery, and methods for drug design and development. After a brief overview of kinases and kinase inhibitors, subsequent chapters discuss individual kinases that are representative of the wider kinases and kinase families, including their roles in disease pathogenesis, underlying mechanisms, potential inhibitors and their modes of action for therapeutic modulation.
Several potential drugs under different stages of clinical trials are discussed, including their relevance to cancer, diabetes, obesity, cardiovascular, neurological, and auto-immune and inflammatory disease, among other disorders. The book also addresses the challenges and opportunities for future kinase inhibitor development.
- Provides a thorough overview of kinase inhibitor biology and its role in disease progression and modulation
- Examines protein kinase inhibitor drugs in various stages of clinical trials and development
- Offers methods and protocols for protein kinase inhibitor research studies and drug design and development
- Includes chapter contributions from international leaders in the field
Basic and translational researchers in biochemistry, molecular biology, cellular biology, genetics, pathology, oncology; life science researchers; biotechnologists; developmental biologists. Clinicians and graduate students in the biosciences
1. Kinase Inhibitors: An Overview
Sabeeha Ali, Manzar Alam and Md. Imtaiyaz Hassan
2. Protein Kinase Inhibitors and cancer targeted therapy
Azadeh Hekmat and Ali Akbar Saboury
3. Drug discovery for cancer therapy with special reference to inhibitors of protein kinase pathway
Chirasmita Nayak and Sanjeev Kumar Singh
4. An insight on PI3K/Akt/mTOR inhibitors in cancer: opportunity and translational perspectives
Javed Ahmad
5. Recent advances in the therapeutic development of ERK inhibitors
Md. Imtaiyaz Hassan
6. Emerging small-molecule inhibitors of ATM kinase targeting cancer therapy
Md. Imtaiyaz Hassan
7. Targeting Pyruvate Kinase M2 Signaling for Development of Effective Cancer Therapy
Md. Imtaiyaz Hassan
8. Serum and glucocorticoid-regulated kinase 1: A potential target for anticancer therapy
Md. Imtaiyaz Hassan
9. AKT inhibitors in cancer therapy
Md. Imtaiyaz Hassan
10. Aurora kinase: An emerging potential target in therapeutics
Hem Chandra Jha
11. The Retroactive and Future Potentials of Aurora Kinases in the Treatment of Cancer
Hardik Bhatt, Keerti Vishwakarma and Suman Shaw
12. Targeting the altered tyrosine kinases in colorectal cancer: from inhibitors to drugs
Sameer Srivastava
13. PTEN-induced kinase1 (PINK1): Structure, Functions and Role in Human Disease
Tooba Naz Shamsi and Michael James
14. Rho associated protein kinase 1 and 2 (ROCK1&ROCK2) as a potential emerging therapeutic drug target in Alzheimer's disease
Ghulam Md Ashraf
15. PDK inhibitors as therapeutic agents: An Overview
Lajpreet Kaur, Mallika Pathak, Sidhartha Dan, Rahul Singhal, Vinod Kumar and Himanshu Ojha
16. Polo-like kinases (PLKs): an antimitotic target
Divya Dube
17. Src Kinase: An Attractive Therapeutic Target for Prostate Cancer
Rajnikant Raut, Parth Gupta, Taruna Saini, Parul Mishra and Ashish Misra
18. Kinase inhibition in Alzheimer's disease
Soghra Bagheri and Ali Akbar Saboury
19. Therapeutic Targeting of Glycogen Synthase Kinase-3: Strategy to address neurodegenerative diseases
Md. Imtaiyaz Hassan
20. Microtubule Affinity Regulating Kinase 4: a potential drug target from cancers to neurodegenerative diseases
Narendran Annadurai and Viswanath Das
21. Receptor tyrosine kinase-like orphan receptors ROR1/2: Insights into the mechanism of action, inhibition, and therapeutic potentialIndrakant
K. Singh
22. Therapeutic Potential of Leucine Rich Repeat Kinase 2 (LRRK2) Inhibitors for Parkinson’s Disease Treatment
Parul Mishra, Subhashree Sahoo, Amrita Arpita Padhy, Varsha Kumari and Kummari Shivani
23. Calcium calmodulin dependent protein kinase as potential drug target
Md. Khurshid and A. Khan
24. Therapeutics of Platelet derived growth factor (PDGF) and signaling in different organs
Eijaz Ahmed Bhat
25. EGFRC797S mutation and fourth generation EGFR tyrosine kinase inhibitors (EGFR-TKIs)
Debasis Das
26. Bacterial Histidine Kinases as potential Antibacterial Drug Targets
Pravindra Kumar
27. Bacterial Protein Kinases: a target to inhibit the bacterial infections
Saroj Sharma and Vishvanath Tiwari
28. Nanotechnology-based targeted delivery systems for Protein Kinase inhibitors in Cancer therapy
Anita Kamra Verma
- Edition: 1
- Published: May 19, 2022
- Imprint: Academic Press
- Language: English
MH
Md. Imtaiyaz Hassan
Dr. Md. Imtaiyaz Hassan, Ph.D., FRSB., FRSC., is Assistant Professor at the Centre for Interdisciplinary Research in Basic Sciences, in Jamia Millia Islamia, New Delhi, India. His research focuses on and design and development of potent and selective kinase inhibitors, as well as understanding the mechanism of folding and dynamic behavior of potential drug targets. Dr. Hassan has published widely in such peer reviewed journals as the International Journal of Biological Macromolecules, Spectrochimica Acta, Scientific Reports, and the OMICS A Journal of Integrative Biology.
Affiliations and expertise
Assistant Professor, Centre for Interdisciplinary Research in Basic Sciences, Jamia Millia Islamia, New Delhi, IndiaSN
Saba Noor
Dr. Saba Noor is a Research Associate at the Centre for Interdisciplinary Research in Basic Sciences, Jamia Millia Islamia, New Delhi, India. Dr. Noor has expertise in molecular oncology, and her current research interests lie in development of kinase inhibitors for use in cancer therapeutics. She has published in such peer reviewed journals as Frontiers in Microbiology and International Journal of Biological Macromolecules, among other journals.
Affiliations and expertise
Research Associate, Centre for Interdisciplinary Research in Basic Sciences, Jamia Millia Islamia, New Delhi, IndiaRead Protein Kinase Inhibitors on ScienceDirect